Bronchodilators are widely used in Cystic Fibrosis (CF), due to hyperreactivity secondary to bronchial damage and/or atopy. They improve sintomatology and prevent bronchoconstriction associated with treatments. Many show acute improvement of FEV1 following b-agonist administration, but response varies over time. A sub-group has acute airways obstruction reversible by b-agonists and atopy, often revealed by increased IgE. These patients may benefit more from bronchodilators chronic use. Aims: To determine the prevalence of bronchodilation responsiveness and its association with IgE in CF pediatric patients. Methods: Retrospective study of all patients over 5 years-old followed in our CF Center during 2008 that had 2 lung function tests (LFT) and IgE determination. Data collected included: demographics, IgE and LFT with bronchodilation test using inhaled salbutamol. An increase in FEV1 10% was considered significative. Results: 35 patients fulfilled the inclusion criteria. The median age was 13 years(±4.2). Global severety of lung disease was mild (FEV1 76.2±27.7%). Positive bronchodilation test was found in 34.2% and 11.4% mantained responsiveness in 2 LFT. 42.9% patients had increased IgE, 40% of whom had bronchodilation. There was no association between increased IgE and responsiveness. Patients with bronchodilation responsiveness had lower FEV1 (74.9% vs 77%; p > 0.05) as did those with increased IgE (72.6% vs 78.9%; p > 0.05). Discussion: In our study many patients had bronchodilator responsiveness, though few showed consistent response over time. Increased IgE prevalence was high. Both bronchodilation and increased IgE were associated with lower FEV1. Studies are needed to determine the real benefits of b-agonists use in the long term in patients with and without atopy.
268 Rationale for a low dose liposomal Ciclosporin A for inhalation via a customised eFlow ® electronic nebuliser to prevent and treat bronchiolitis obliterans (BO) A modified scoring system based on chest MRI was designed to objectively grade the severity and extention of lung disease in CF. 15 patients with CF underwent chest morphological MRI. Functional MR ventilation was also assessed by using dedicated Oxigen-related sequences. All patients also underwent a HRCT within 7 days.MRI was scored using a modified Baumann-CT scoring system.MRI score of each patient was calculated on the basis of bronchiectasis and divided into 4 score-group. Extra-findings such as: air trapping, ventilation defects, micetoma and pancreatic changes were also recorded.A good morphological correlation was found between 2 radiologists to evaluate mucus plugging and atelectasis, even in patients with a low grade of the disease. All MRI findings were also confirmed by CT with a very high agreement between the 2 radiologists and both the techniques. Fungal infection was found in 3 patients.MRI showed in these patients a better delineation of the central cavitation of the micetoma as compared to HRCT. Severe air trapping was found by CT in 4 patients. In 3 of these it was recognized also by MRI whom also showed focal and segmental defects when pure O2 was inhaled. Sensitivity, specificity and accuracy for the scoring system were respectively 99%, 96% and 97% for MRI, compared to CT. A complete agreement was reached for bronchiectasis. MRI might be a feasible and not invasive diagnostic imaging technique to stage pediatric patients with cystic fibrosis avoiding exposure toXR. Further studies will able to confirm and improve our results. The severity of chronic bronchopulmonary inflammation is the limited factor for surviving of CF patients. Novel therapies (inhaled antibiotics, rhDNAse, respiratory physiotherapy) and multidisciplinary approach results to rising median surviving age and better QoL as well. Lung function testing is an important marker of lung impairment, but it seems to be less sensitive in comparison to HRCT of lung in CF. In previous study (Belfast, 2003) we concluded that HRCT was more sensitive method of evaluating pathologic changes in CF lung (mucus plugging, thickening of airway wall, bronchiectasiones, inflammatory process, air-trapping, emphysema) than LFT, which could be in normal ranges in patients with advanced CF disease. According to localisation and type of changes we can start with segmental physiotherapy, more intensive mucolytic therapy (rhDNA), anti-inflammatory therapy. Aims: To evaluate the changes of lung function (LFT) and morphologic changes in HRCT in 8 years period and correlate them with genotype and clinical status of patients.
HRCT and LFT in monitoring CF lung disease

Methods:
We examinated 116 CF pts with more than 3 HRCT (every 2 yeras) examinations done from the year 2000. Results: 79 pts with severe CFTR mutations (mean age: 18.8 years, FVC: 86.4%, FEV1: 83.7%, MEF50: 69.9%). Staging according Bhalla: 6.97 for right lobe, 6.71 for left lobe. 37 pts with mild CFTR mutations with normal LFT (FVC: 89.4%, FEV1: 89.3%, MEF50: 80.3%), but significantly lower HRCT score (RL: 2.97, LL: 2.53). Conclusion: Mean HRCT score and LFT did not change in most CF patients with intensive standard therapy in this time period. HRCT score correlates with CFTR genotype and compliance with therapy.
